ANGUS Unveils a New Division: ANGUS Life Sciences
ANGUS Chemical Company , a leading manufacturer and marketer of nitroalkanes and their derivatives, today announced the launch of its new life sciences division, ANGUS Life Sciences. Formed to provide a dedicated focus on the specific needs of the life sciences industry, ANGUS Life Sciences supplies customers in the biotechnology, pharmaceutical and agriculture markets with the high-quality buffers, biochemicals, biomolecules and intermediates they have come to rely on.
“Our new ANGUS Life Sciences division is built on our rich, 70-year legacy of manufacturing specialized chemistries, such as our TRIS AMINO® ,” said Mark Henning, President and CEO of ANGUS. “We understand the importance of aligning and controlling stability, consistency, quality and compliance across the duration of product lifecycles. This new business division is a testament to our commitment to our life sciences customers by providing premium fine and specialty chemistries they need to develop their best products for R&D, scale-up and production.”
Based in the United States, ANGUS Life Sciences is the world’s only fully integrated manufacturer of TRIS AMINO buffers, based on their unique nitroalkane chemistry. In addition to TRIS AMINO, ANGUS Life Sciences also provides other high-quality offerings, including biological buffers, biochemicals, biomolecules and amino acids.
“We’re dedicated to what matters most to our customers – quality products, traceable and auditable supply chains, and optimized cost-effectiveness and efficiency. Through ANGUS Life Sciences, we strive to be an innovative partner to our customers within the life sciences industry,” said Dave Green, Vice President of R&D at ANGUS. “We look forward to helping our customers develop winning products, conduct successful launches and achieve faster time-to-market.”
Customer-specific testing, packaging and labeling are also available through ANGUS Life Sciences, whose facilities are cGMP compliant and ISO 9001:2008 certified.
For more information about ANGUS Life Sciences, please visit: angus.com/markets/life-sciences
About ANGUS Chemical Company
As the world’s only company dedicated to producing nitroalkanes and their derivatives, ANGUS Chemical Company stands apart as a fine and specialty chemical company uniquely suited to solving formulation challenges in industries such as Home and Personal Care; Industrial Specialties including paints and coatings, metalworking fluids and electronics; and Life Sciences concentrated on pharmaceutical, biotechnology and agriculture applications—backed by unmatched application expertise and global customer support.
Our legacy of providing exclusive and proprietary chemistries has spanned over 70 years. Currently a leading supplier of specialty additives, intermediates, performance enhancers and process aids, we help customers deliver greatly enhanced process and product performance. Simply put, we make the best perform better.
Chempetitive Group for ANGUS Chemical Company
Trisha Rule, 1-858-230-4949
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ADC-THERAPEUTICS11.12.2017 07:32 | pressemeddelelse
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
ADC-THERAPEUTICS11.12.2017 07:02 | pressemeddelelse
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
FL-GA-TELESIS11.12.2017 06:03 | pressemeddelelse
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum